| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 162.21 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Anaemia is a common complication in haemodialysis patients. This condition is
associated to a decreased bone marrow production of erythrocytes, mainly due to
the inability of the failing kidneys to secrete erythropoietin (EPO). The
introduction of recombinant human EPO (rhEPO) therapy led to a significant
reduction in anaemia and improved patients’ quality of life. However, there is a
marked variability in the sensitivity to rhEPO, with up to 10-fold variability in
dose requirements to achieve correction of anaemia. Approximately 5-10% of the
patients show a marked resistance to rhEPO therapy. rhEPO resistance is associated to an increased morbidity and mortality of haemodialysis patients. In this paper a revision of the mechanisms underlying resistance to rhEPO therapy will be performed, with particular emphasis on inflammatory cytokines, leukocyte activation, iron status, and erythrocyte damage.
Description
Keywords
Haemodialysis Resitance to rhEPO therapy Erythropoietin Inflammation Leukocyte activation Iron status Erythrocyte damage
Pedagogical Context
Citation
COSTA, Elísio; BELO, Luís - Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage. Journal of Nephrology and Renal Transplantation. ISSN 1918-025X. Vol. 2, n.º 3 (2009), p. 66–83
Publisher
OmniScientia